Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Phase II Study of Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Sponsor: Japan Adjuvant Study Group of Pancreatic Cancer
This PHASE2 trial investigates Pancreatic Cancer and is currently completed. Japan Adjuvant Study Group of Pancreatic Cancer leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2018 — Nov 2020 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Japan Adjuvant Study Group of Pancreatic Cancer
- Japan Agency for Medical Research and Development
- Pharma Valley Center
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Asahikawa, Japan , Chiba, Japan , Chuo-ku, Japan , Fukuoka, Japan , Fukuyama, Japan , Hamamatsu, Japan , Hirosaki, Japan , Kashiwa, Japan , Kawasaki, Japan , Kita-adachigun Inamachi, Japan and 11 more locations